Get started
Author

Joanne Riemer

Observed names: Joanne B. Riemer, Riemer, Joanne
ORCID: 0000-0001-7997-0680
Observed ORCID: 0000-0001-7997-0680
OpenAlex ID: A5049554147
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
2020 · Zhihao Lu, Jianling Zou, et al. · Nature · 328
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
2023 · Jarushka Naidoo, Catherine Murphy, et al. · Journal for ImmunoTherapy of Cancer · 165
PDF
A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
2019 · Jarushka Naidoo, Jiajia Zhang, et al. · Journal of the National Comprehensive Cancer Network · 107
PDF
Chronic immune checkpoint inhibitor pneumonitis
2020 · Jarushka Naidoo, Tricia R Cottrell, et al. · Journal for ImmunoTherapy of Cancer · 100
PDF
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al. · Clinical Cancer Research · 74
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
2021 · Jarushka Naidoo, Karisa C Schreck, et al. · Journal for ImmunoTherapy of Cancer · 67
PDF
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
2019 · Kellie N. Smith, Nicolas J. Llosa, et al. · Journal for ImmunoTherapy of Cancer · 45
PDF
A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.
2018 · Jarushka Naidoo, Laura Cappelli, et al. · Journal of Clinical Oncology · 20
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers
2020 · Jarushka Naidoo, Karisa Schreck, et al. · 4
A multidisciplinary immune-related toxicity (IR-Tox) program for immune-related adverse events: A two-year experience.
2020 · Aanika Balaji, Jiajia Zhang, et al. · Journal of Clinical Oncology · 2
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
2019 · Kellie N. Smith, Nicolas J. Llosa, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Data from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al. · 1
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al. · 1
Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.
2020 · Jarushka Naidoo, Karisa C. Schreck, et al. · Journal of Clinical Oncology · 1
Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025 · Samuel Rosner, Joshua E. Reuss, et al.
PDF
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025 · Samuel Rosner, Joshua E. Reuss, et al.
Abstract 6551: Comprehensive genomic and transcriptomic analyses capture the effects of epigenetic therapy priming on immune checkpoint blockade response in non-small cell lung cancer
2024 · Blair V. Landon, Kristen A. Marrone, et al. · Cancer Research
Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al.
PDF
Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al.
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al.
Data from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al.
Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community.
2020 · Latha Shivakumar, Christine B. Weldon, et al. · Journal of Clinical Oncology
Additional file 1: of Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
2019 · Smith, Kellie, Llosa, Nicolas, et al. · Figshare
Works count: 24
Citation count: 928
H-index: 9
I10-index: 9
Year
Topic
Type